Pyrotinib (C32H31ClN6O3, 583.08), developed by Hengrui Medicine, was approved by the Chinese FDA in 2018, with the indication of HER2-positive advanced breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.